

II. Remarks

A. Status of the Claims

Claims 2-4, 10, 29-83, 99-101, 113-114, and 126 are cancelled. Claims 1, 9, 11, 84-87, 97-98, 102-103, 115 and 127 are amended. Claim 129 is added. Claims 1, 5-9, 11-28, 84-98, 102-112, 115-125, and 127-129 are pending.

B. Support for Amended and Added Claim Language

Support for amended claim language and added claim language is found throughout the specification and claims as originally filed.

Support for language of amended Claims 1, 98, and 102 is found in FIG. 3, in Claims 9 and 11 as originally filed, and in the figure legend for FIG. 3 on page 8, line 3; support for language of amended Claim 84 is found in Claim 84 as originally filed and in Claim 1; support for language of amended Claim 86 is found in Claim 1; support for language of amended Claims 97, 115, and 127 is found in FIG. 5 and in the figure legend on page 8, lines 6-7; and support for language of added Claim 129 is found in FIG. 3, the figure legend for FIG. 3 on page 8, line 3, and in the Office Action at pages 3, 4, and 5. Applicants submit that no new matter has been introduced by the amended claim language or the added claim language.

C. Rejection of Claims under 35 U.S.C. §112

Office Action

The Office Action states that adequate written description and adequate enablement do not exist in the instant application for all possible hyperactive reverse transcriptases comprising one or more point mutations. Office Action at pages 2-7.

Response

Pending claims have been amended to recite point mutations at H638 or F155. Applicants, therefore, respectfully request that the rejection under 35 U.S.C. §112 be withdrawn.

D. Rejection of Claims under 35 U.S.C. § 102(b)

Claims 46, 47, 49, 50, 57, 58, 86-96, 127 and 128 were rejected as anticipated by Gao *et al.* U.S. Patent No. 6,136,582.

Response

Claims 46, 47, 49, 50, 57, and 58 are cancelled.

To anticipate a claim, each and every element of the claim must be found in a single prior art reference. MPEP § 2131.

Independent Claim 86 has been amended to depend from Claim 1, which claim was not subject to this rejection. Therefore, amended Claim 86 is not anticipated by Gao *et al.* Independent Claim 127 has been amended to recite the point mutation H638G. Gao *et al.* do not teach or suggest a point mutation at amino acid 638. Therefore, Gao *et al.* cannot anticipate Claim 127, or Claim 128 which claim is dependent upon Claim 127.

Applicants respectfully request withdrawal of the rejection over Gao *et al.*

E. Conclusion

Applicants believe that the foregoing remarks fully respond to all outstanding matters for this application. Applicants respectfully request reconsideration of the claimed invention.

Should there be any questions or comments regarding this document, the Examiner is invited to contact Applicants' representative, Gloria L. Norberg at 512-721-3654 for discussion.

Respectfully submitted,



Gloria L. Norberg, Ph.D., Patent Agent
Reg. No. 36,706
Agent for Applicants

Ambion Inc.
2130 Woodward St.
Austin, Texas 78744
(512) 721-3654
(512) 651-0201 (facsimile)

Date: September 26, 2007